Insights about U.S. Stocks that landed in the Green-Zone during Thursday’s trade, are depicted underneath:
Incyte Corporation NASDAQ:INCY)’s shares picked up 4.62%, and closed at $91.97, hitting new 52-week high of $94.48.
Incyte Corporation (INCY), declared that Steven H. Stein, MD, has been designated Senior Vice President and Chief Medical Officer, effective right away. Dr. Stein was formerly SVP, US Clinical Development & Medical Affairs at Novartis Oncology US, and he will be responsible for clinical and medical strategy and operations across Incyte’s extensive oncology portfolio.
He will join the executive administration team of Incyte, and report to Richard S. Levy, MD, Executive Vice President and Chief Drug Development Officer.
“I am tremendously excited and privileged to be joining Incyte,” added Steven Stein, MD, Incyte’s Chief Medical Officer. “This is an exciting time in the drug development space, and with its innovative products and talented team, I am eager to get started at Incyte.”
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical corporation focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology.
Raptor Pharmaceutical Corp (NASDAQ:RPTP), raised 4.56%, and closed at $10.77.
Formerly on February 26, Raptor Pharmaceuticals Corp. (RPTP), stated financial results for the fourth quarter and year ended December 31, 2014 and offered an update on recent corporate developments.
Global net product sales for PROCYSBI(R) (cysteamine bitartrate) delayed-release capsules were $17.3 million for the fourth quarter ended December 31, 2014 contrast to $10.2 million for the same period in 2013. Global net product sales for PROCYSBI for the full year 2014 were $69.5 million contrast to $16.9 million for the same period in 2013. Global net product sales in 2014 came in at the top end of the corporation’s guidance range of $65 to $70 million.
Raptor stated a net loss on a GAAP basis of $18.9 million for the fourth quarter, or $0.29 per share, and a net loss of $52.5 million, or $0.83 per share, for the full year.
The corporation made several key hires in the fourth quarter of 2014 and in January 2015 to build the executive administration team and designated two new members to the Board of Directors in January 2015.
The Centre Hospitalier Universitaire or CHU, of d’Angers, France presented 18-month data from Phase 2/3 (Cyst-HD) study of RP103 in Huntington’s disease at the Huntington’s Study Group meeting in November 2014. Data demonstrated that RP103 improved Total Motor Score, or TMS, by 2.2 points in the modified intent-to-treat (mITT) population.
Raptor is establishing 2015 financial guidance with global net product sales for PROCYSBI between $80 and $90 million and non-GAAP operating expense, not including non-cash stock-based compensation expense, between $115 and $125 million.
Raptor Pharmaceutical Corp. is a global biopharmaceutical corporation focused on the development and commercialization of life-altering therapeutics that treat rare, debilitating and often fatal diseases. The corporation is engaged in multiple therapeutic areas such as nephropathic cystinosis, Huntington’s disease (HD), nonalcoholic steatohepatitis (NASH), Leigh syndrome and other mitochondrial diseases.
IsoRay, Inc (NYSEMKT:ISR), enhanced 4.19%, and closed at $1.74.
Formerly on February 18, IsoRay, Inc. (ISR), declared its financial results for the quarter and six months ended December 31, 2014. With over $20,000,000 of cash on hand and no debt, IsoRay is positioned to be a dominant player in the brachytherapy cancer treatment market.
IsoRay’s team remains focused in diversifying its product offerings through institutional based studies designed to address various aggressive cancers that to date often fail current standard of care options. Administration is hopeful that the lingering decline in the prostate market may be bottoming out. Administration anticipates seeing modest gains in IsoRay’s market share in addition to some proceed growth in the coming quarters. We practiced a negative influence on our international sales efforts during the quarter ended December 31, 2014, with the devaluation of the Euro causing our products to become higher in price, making it more difficult to attract new adopters in this market.
IsoRay continues to invest in R&D data protocols geared to showing improved efficacy over current cancer treatments while providing the patient with an improved quality of life experience. Several new studies are predictable to launch in the near future in various body sites. These will likely comprise focal treatment for prostate cancer, a head and neck cancer study and a GliaSite balloon catheter brain cancer treatment utilizing Cesitrex, our liquid form of Cesium-131. IsoRay Chairman and CEO Dwight Babcock commented, “Clinical evidence offered through protocols performed by major medical centers that prove utilizing Cesium-131 is either equal to or better than the current standard of care alternatives, with patients enjoying an improved quality of life, remains the key to IsoRay’s success. These studies also aid in generating awareness and ultimately general adoption by community hospitals and physicians, which will in turn drive consumers to our product offerings. To this end IsoRay is totally committed and given this growing acceptance and interest in our now published results, we remain committed to our planned sales and marketing objectives, which we believe will contribute to long term growth and achieving profitability.”
IsoRay, Inc., through its partner, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which is expanding brachytherapy options throughout the body.
WisdomTree Investments, Inc (NASDAQ:WETF), enhanced 4.10%, and closed at $20.29, hitting new 52-week high of $20.55.
WisdomTree Investments, Inc. (WETF), an exchange-traded fund and exchange-traded product sponsor and asset manager, declared the launch of the WisdomTree Europe Hedged SmallCap Equity Fund (EUSC) on the NYSE Arca. EUSC seeks to provide exposure to small capitalization stocks within European equity markets while hedging exposure to the euro. The Fund has a net expense ratio of 0.58%.
WisdomTree Investments, Inc., through its auxiliaries in the U.S. and Europe, is an exchange-traded fund and exchange-traded product sponsor and asset manager headquartered in New York.
